Compounds > pyrazines
Page last updated: 2024-08-21

pyrazines and xanomeline

pyrazines has been researched along with xanomeline in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (66.67)18.2507
2000's1 (33.33)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bymaster, FP; Calligaro, DO; Deeter, JB; Merritt, L; Mitch, CH; Olesen, PH; Peters, SC; Sauerberg, P; Sawyer, BD; Shannon, HE; Sheardown, MJ; Swedberg, MD; Ward, JS1
Abou-Gharbia, M; Boast, CA; Husbands, GM; Moyer, JA; Sabb, AL; Stein, RP; Tasse, RP; Tokolics, J1
Abou-Gharbia, M; Bartolomeo, AC; Boast, CA; Buccafusco, JJ; Husbands, MG; Kille, N; Morris, H; Moyer, JA; Rosenzweig-Lipson, S; Sabb, AL1

Other Studies

3 other study(ies) available for pyrazines and xanomeline

ArticleYear
Functionally selective M1 muscarinic agonists. 3. Side chains and azacycles contributing to functional muscarinic selectivity among pyrazinylazacycles.
    Journal of medicinal chemistry, 1995, Sep-01, Volume: 38, Issue:18

    Topics: Animals; Bridged Bicyclo Compounds; Bridged Bicyclo Compounds, Heterocyclic; Cell Line; Male; Mice; Muscarinic Agonists; Pyrazines; Pyridines; Rats; Rats, Sprague-Dawley; Receptors, Muscarinic; Structure-Activity Relationship; Thiadiazoles

1995
Discovery of a highly potent, functionally-selective muscarinic M1 agonist, WAY-132983 using rational drug design and receptor modelling.
    Bioorganic & medicinal chemistry letters, 1999, Jul-19, Volume: 9, Issue:14

    Topics: Administration, Oral; Animals; Bridged-Ring Compounds; Carbachol; Cerebral Cortex; CHO Cells; Cognition Disorders; Computer Simulation; Cricetinae; Crystallography, X-Ray; Drug Design; Drug Evaluation, Preclinical; Humans; Macaca mulatta; Maze Learning; Models, Molecular; Muscarinic Agonists; Phosphatidylinositols; Protein Conformation; Pyrazines; Pyridines; Rats; Receptor, Muscarinic M1; Receptors, Muscarinic; Salivation; Structure-Activity Relationship; Thiadiazoles

1999
The preclinical pharmacological profile of WAY-132983, a potent M1 preferring agonist.
    The Journal of pharmacology and experimental therapeutics, 2000, Volume: 292, Issue:2

    Topics: Animals; Aziridines; Behavior, Animal; Brain; Bridged-Ring Compounds; Choline; Choline O-Acetyltransferase; Cognition; Dose-Response Relationship, Drug; Drug Interactions; Female; Frontal Lobe; Hippocampus; Hypothermia; Macaca mulatta; Male; Mice; Muscarinic Agonists; Neuromuscular Blocking Agents; Pyrazines; Pyridines; Rats; Rats, Sprague-Dawley; Salivation; Scopolamine; Thiadiazoles; Time Factors; Visual Cortex

2000